Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.59 |
| ▸ | CA1 | P00915 | 7/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | CA12 | O43570 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18590675 | 0.89 | CA2 (0.57) | CA2CA1CA9CA12L3MBTL1 | |
| SCHEMBL21546369 | 0.84 | MAPT (0.55) | L3MBTL1MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL17620063 | 0.80 | MAPT (0.51) | L3MBTL1MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL17620219 | 0.80 | MAPT (0.51) | L3MBTL1MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL30628487 | 0.80 | CA1 (0.86) | CA2CA1CA9CA12KDM4E | |
| SCHEMBL13401871 | 0.74 | CA1 (1.00) | CA2CA1CA9CA12KDM4E | |
| SCHEMBL6631272 | 0.71 | CA2 (0.55) | CA2CA1CA9CA12KDM4E | |
| SCHEMBL11887649 | 0.71 | CA1 (0.77) | CA2CA1CA9CA12L3MBTL1 | |
| SCHEMBL29609330 | 0.70 | KMT2A (0.73) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL28582955 | 0.70 | MEN1 (1.00) | CA2CA1CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571409-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210340126-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-11-04 | — | — | US | disclosed |
| US-11059808-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210093608-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2021-04-01 | — | — | US | disclosed |
| US-10869856-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200231571-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-07-23 | — | — | US | disclosed |
| US-20200163935-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10576059-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190343797-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3194030-B1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10413527-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190070146-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2019-03-07 | — | — | US | disclosed |
| US-20170273943-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-28 | — | — | US | disclosed |
| WO-2017035127-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016044808-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576059-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-20210093608-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-10413527-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-10869856-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-20190070146-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-20200163935-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-20170273943-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-20200231571-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-20190343797-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-20210340126-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-11571409-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
| US-11059808-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | CA2 4810/4885CA1 4885/4885CA9 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.